Cybin Inc. CYBN Archives - Page 11 of 18

WednesdayJan 12, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes ‘Milestone’ Step with USPTO Notice of Allowance CYB004

Cybin awarded notice for company’s innovative treatment of anxiety disorders Approval demonstrates company’s dedication to discovery and development of psychedelic-based compounds for addressing mental health Anxiety disorders rank among the most common mental illnesses in the country Cybin (NEO: CYBN) (NYSE American: CYBN) has taken another step forward in its strategic plan to strengthen its position as leading innovator in developing putative psychedelic compounds. The company has received a Notice of Allowance from the U.S. Patent and Trademark Office (“USPTO”) for its patent application for an innovative treatment of anxiety disorders (https://ibn.fm/8hMWh). Cybin announced that it has been awarded a USPTO…

TuesdayJan 11, 2022 12:27 pm

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures IRB Approval for Feasibility Study Using Kernel’s Quantitative Neuroimaging Technology

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that an Institutional Review Board (“IRB”) has approved a company-sponsored feasibility study. The study will use Kernel’s quantitative neuroimaging technology, Kernel Flow, to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. As part of its sponsorship of the feasibility study, Cybin will retain an exclusive interest in any innovations discovered or developed through its independent analysis of the findings. “By leveraging the Kernel Flow technology, we may have the ability to measure longitudinal brain activity before, during and after a psychedelic experience, and…

MondayJan 10, 2022 10:14 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Participation in Upcoming Events Recognizes Company Expertise

CEO to participate in panel discussion, fireside chat focusing on psychedelics The company is engineering next-generation psychedelic molecules as it works to transform the mental health treatment landscape CYBN is implementing a three-pillar strategy Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is gaining recognition as a leader in the psychedelic space. Evidence of this can be seen in the Cybin CEO’s upcoming participation in two virtual investor conferences (https://ibn.fm/1zAF4). The company announced that CEO Doug Drysdale has been invited to participate in a panel discussion titled "Psychedelics: More Than Just a Trip" during…

FridayJan 07, 2022 10:56 am

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes that Adelia Has Reached Milestone Achievement

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has announced that its wholly owned subsidiary, Adelia Therapeutics Inc., has a achieved a significant milestone. Specific milestones outlined in the Dec. 4, 2021, contribution agreement define what actions are to be taken when certain milestones are reached. When this specific milestone, identified as Year 2 Q1 (v), is reached, the agreement calls for 15,611.4 class B common shares to be issued to Adelia shareholders; those shares are exchangeable for common shares in Cybin capital in accordance with parameters defined by the agreement. Adelia is committed to…

ThursdayJan 06, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Key Meeting with UK Regulatory Agency

Meeting takes company a step closer to advancing its lead investigational candidate CYB003 into clinical development CYB003 is designed for the treatment of two significant conditions: major depressive disorder (“MDD”) and alcohol use disorder (“AUD”) CEO notes that CYB003 has the potential to achieve better patient outcomes The coming year holds significant promise for Cybin (NEO: CYBN) (NYSE American: CYBN) for numerous reasons. The biopharmaceutical company has seen significant success in the execution of its strategic focus on progressing psychedelics to therapeutics, including its recent announcement that company representatives will hold a scientific advice meeting with the UK Medical and Healthcare…

TuesdayJan 04, 2022 2:00 pm

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Support Low-Cost/No-Cost Psychedelic Clinic for Underserved Communities

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is marking key milestones to revolutionize mental health care. Among these, the company recently secured a grant for the first-ever psychedelic treatment clinic at Lenox Hill Hospital. The hospital is part of Northwell Health, the largest health care system in New York State, and serves marginalized communities on the Upper East Side of Manhattan. Lenox Hill is working to become one of the first hospital-based clinical sites to offer psychedelic medicine in the United States. A recent article quotes Cybin Chief Clinical Officer Dr. Alex…

TuesdayJan 04, 2022 10:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Milestone Notice of Allowance for Revolutionary Treatment of Anxiety Disorders

USPTO notice marks important milestone in the expansion of CYBN’s intellectual property portfolio Once issued, patent may have opportunity to cover a broad range of claims Anxiety disorders are one of the most common mental illnesses in the United States Cybin (NEO: CYBN) (NYSE American: CYBN) has taken another step forward in its commitment to progressing Psychedelics to Therapeutics(TM). The biopharmaceutical company has received a notice of allowance from the U.S. Patent and Trademark Office (“USPTO”) in regard to its patent application connected to its investigational deuterated psychedelic tryptamine compound for the potential treatment of anxiety disorders (https://ibn.fm/fpjXm). “The receipt of…

TuesdayDec 28, 2021 1:41 pm

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Witnessing Swift Advancement in R&D Pipeline, Overall Business

Cybin (NYSE American: CYBN) (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently released its financial and operating report for Q2 2021, with notable company milestones and achievements highlighted. The company plans to move through the ongoing remaining preclinical studies for its CYB003 novel deuterated psilocybin analog and submit an investigational new drug application and clinical trial application in the second quarter of 2022 in the U.S. and the U.K., respectively. “Other notable company achievements during the quarter include the U.S. Drug Enforcement Agency’s approval of a Schedule I manufacturing license for Cybin’s…

WednesdayDec 22, 2021 9:55 am

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Issues 2021 Year-End Summary

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has provided a year-end summary of its major milestones and key catalysts from 2021 that it believes have positioned the company for a transformative 2022. “2021 was an exciting year for Cybin. We expanded our organization from five to more than 55 employees across four countries and have established an operating ecosystem of nearly 50 partners and vendors that have supported more than 90 preclinical studies and numerous patent and investigational new drug filings over the past 12 months,” said Cybin’s CEO Doug Drysdale in…

TuesdayDec 21, 2021 11:49 am

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation in Upcoming January Events

Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, will be participating in two premier events: the 11th annual LifeSci Partners Annual Corporate Access Event and the H.C. Wainwright Bioconnect Conference. Cybin CEO Doug Drysdale will participate in both upcoming virtual investor events. At the LifeSci Partners event, scheduled for Jan. 5–7, 2021, Drysdale will be involved in a panel discussion titled “Psychedelics: More Than Just a Trip.” The panel is slated for Wednesday, Jan. 5, at 10 a.m. ET. At the H.C. Wainwright Bioconnect Conference, Drysdale willparticipate in a fireside chat, which is scheduled…

Site Search

Company Search

Tag: Cybin Inc. CYBN